NO20053678L - Kombinasjonsterapi for behandling av immuninflammatoriske forstyrrelser - Google Patents

Kombinasjonsterapi for behandling av immuninflammatoriske forstyrrelser

Info

Publication number: NO20053678L
Authority: NO; Norway
Prior art keywords: treatment; combination therapy; inflammatory disorders; nsidi; immune inflammatory
Prior art date: 2003-02-14

Application number

NO20053678A

Other languages

English (en)

Norwegian (no)

Other versions

NO20053678D0 (no

Inventor

Edward Roydon Jost-Price

Brendan Smith

Benjamin A Auspitz

Bradley B Brasher

Noah Sachs

Todd W Chappell

Palaniyandi Manivasakam

Original Assignee

Combinatorx Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-02-14

Filing date

2005-07-29

Publication date

2005-09-12

2005-07-29 Application filed by Combinatorx Inc filed Critical Combinatorx Inc

2005-07-29 Publication of NO20053678D0 publication Critical patent/NO20053678D0/no

2005-09-12 Publication of NO20053678L publication Critical patent/NO20053678L/no

Links

238000002648 combination therapy Methods 0.000 title 1
208000027866 inflammatory disease Diseases 0.000 title 1
230000000495 immunoinflammatory effect Effects 0.000 abstract 2
239000002207 metabolite Substances 0.000 abstract 2
102000000521 Immunophilins Human genes 0.000 abstract 1
108010016648 Immunophilins Proteins 0.000 abstract 1
230000001419 dependent effect Effects 0.000 abstract 1
239000003623 enhancer Substances 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
230000003637 steroidlike Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Rheumatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Tropical Medicine & Parasitology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Cardiology (AREA)
Transplantation (AREA)

NO20053678A 2003-02-14 2005-07-29 Kombinasjonsterapi for behandling av immuninflammatoriske forstyrrelser NO20053678L (no)

Applications Claiming Priority (8)

Application Number	Priority Date	Filing Date	Title
US44741503P	2003-02-14	2003-02-14
US44741203P	2003-02-14	2003-02-14
US44755303P	2003-02-14	2003-02-14
US44736603P	2003-02-14	2003-02-14
US44764803P	2003-02-14	2003-02-14
US46475303P	2003-04-23	2003-04-23
US50302603P	2003-09-15	2003-09-15
PCT/US2004/004077 WO2004073614A2 (en)	2003-02-14	2004-02-12	Combination therapy for the treatment of immunoinflammatory disorders

Publications (2)

Publication Number	Publication Date
NO20053678D0 NO20053678D0 (no)	2005-07-29
NO20053678L true NO20053678L (no)	2005-09-12

Family

ID=32913413

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20053678A NO20053678L (no)	2003-02-14	2005-07-29	Kombinasjonsterapi for behandling av immuninflammatoriske forstyrrelser

Country Status (14)

Country	Link
US (1)	US20040224876A1 (pl)
EP (1)	EP1599212A4 (pl)
JP (1)	JP2006517969A (pl)
KR (1)	KR20050110634A (pl)
AR (1)	AR043188A1 (pl)
AU (1)	AU2004212919A1 (pl)
CA (1)	CA2514061A1 (pl)
HR (1)	HRP20050804A2 (pl)
IS (1)	IS8023A (pl)
MX (1)	MXPA05008649A (pl)
NO (1)	NO20053678L (pl)
PL (1)	PL378108A1 (pl)
TW (2)	TW200509958A (pl)
WO (1)	WO2004073614A2 (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9812110D0 (en)	1998-06-06	1998-08-05	Levelrecall Limited	Yttrium oxide based gas mantle
US6861056B2 (en) *	2001-06-05	2005-03-01	Advanced Biotherapy, Inc.	Compositions and methods for treating hyperimmune response in the eye
GB0307864D0 (en) *	2003-04-04	2003-05-14	Novartis Ag	Pharmaceutical composition
US20050192261A1 (en) *	2003-09-15	2005-09-01	Jost-Price Edward R.	Methods and reagents for the treatment of immunoinflammatory disorders
GB0327840D0 (en) *	2003-12-01	2003-12-31	Novartis Ag	Organic compounds
WO2005053665A1 (en) *	2003-12-01	2005-06-16	Vertex Pharmaceuticals Incorporated	Treating infectious diseases using ice inhibitors
US20070020299A1 (en)	2003-12-31	2007-01-25	Pipkin James D	Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US8426475B2 (en) *	2005-04-13	2013-04-23	Astion Development A/S	Treatment of connective tissue diseases of the skin
TW200711649A (en) *	2005-06-17	2007-04-01	Combinatorx Inc	Combination therapy for the treatment of immunoinflammatory disorders
WO2007002120A2 (en) *	2005-06-23	2007-01-04	Duke University	Fungicidal effect by regulating signal transduction pathways
ITMI20051826A1 (it) *	2005-09-29	2007-03-30	Novachem S A	Kit per la somministrazione parenterale di medicamenti
WO2007041677A2 (en) *	2005-10-03	2007-04-12	Combinatorx, Incorporated	Soft tissue implants and drug combination compositions, and use thereof
US20070128289A1 (en) *	2005-12-07	2007-06-07	Zhao Jonathon Z	Nano-and/or micro-particulate formulations for local injection-based treatment of vascular diseases
EP1971865B1 (en) *	2006-01-10	2013-04-17	Colgate-Palmolive Company	Methods of modulating cell surface receptors to prevent or reduce inflammation
TR201807065T4 (tr)	2006-02-02	2018-06-21	Novartis Ag	Tüberöz sklerozis tedavisi.
AU2011205053B2 (en) *	2006-02-02	2013-02-07	Novartis Ag	Tuberous Sclerosis treatment
US8207188B2 (en) *	2006-04-07	2012-06-26	Michalis Nicolaou	Treatment of diseases modulated by a H4 receptor agonist
WO2008031014A1 (en) *	2006-09-08	2008-03-13	Ore Pharmaceuticals Inc.	Method for reducing or alleviating inflammation in the digestive tract
EP2170317A4 (en) *	2007-02-12	2011-03-23	Mike Nicolaou	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), GASTRO-OESOPHAGEAL REFLUX DISEASE (GERD), FOOD ALLERGIES, AND OTHER DISEASES AND GASTROINTESTIN DISORDERS AFFECTED BY APPROPRIATE MANAGEMENT OF HISTAMINE USING A COMBINATION OF INHIBITORS HISTIDINE DECARBOXYLASE, MEDICAMEN
EP2420238A3 (en) *	2007-04-13	2012-03-07	Southern Research Institute	Anti-angiogenic agents
ES2493641T3 (es) *	2007-06-28	2014-09-12	Cydex Pharmaceuticals, Inc.	Administración nasal de soluciones acuosas de corticosteroides
US12370352B2 (en)	2007-06-28	2025-07-29	Cydex Pharmaceuticals, Inc.	Nasal and ophthalmic delivery of aqueous corticosteroid solutions
US9149463B2 (en) *	2007-09-18	2015-10-06	The Board Of Trustees Of The Leland Standford Junior University	Methods and compositions of treating a Flaviviridae family viral infection
US8940730B2 (en)	2007-09-18	2015-01-27	The Board Of Trustees Of The Leland Stanford Junior University	Methods and compositions of treating a Flaviviridae family viral infection
US9101628B2 (en) *	2007-09-18	2015-08-11	The Board Of Trustees Of The Leland Stanford Junior University	Methods and composition of treating a flaviviridae family viral infection
EP2203168B1 (en) *	2007-09-18	2014-07-16	Stanford University	Compositions for treating a flaviviridae family viral infection
EP2309858A4 (en)	2008-07-31	2011-09-14	Dekel Pharmaceuticals Ltd	COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
US8975247B2 (en) *	2009-03-18	2015-03-10	The Board Of Trustees Of The Leland Stanford Junion University	Methods and compositions of treating a flaviviridae family viral infection
US10426752B2 (en)	2009-04-01	2019-10-01	Colgate-Palmolive Company	Menthol-derivative compounds and use thereof as oral and systemic active agents
MY163501A (en)	2009-04-01	2017-09-15	Colgate Palmolive Co	Anti-biofilm carbonate compouns for use in oral care compositions
TWI481870B (zh)	2009-04-01	2015-04-21	Colgate Palmolive Co	用於軟組織疾病診斷及作為用於口腔保健干預的標靶之蛋白質生物標記
AR076177A1 (es)	2009-04-01	2011-05-26	Colgate Palmolive Co	MÉTODO PARA IDENTIFICAR UN COMPUESTO uTIL PARA TRATAR UNA ENFERMEDAD O CONDICIoN DE LA CAVIDAD ORAL
KR101388235B1 (ko) *	2011-09-20	2014-04-24	가톨릭대학교 산학협력단	메클리진을 포함하는 관절염 예방 및 치료용 조성물
IL310969A (en)	2015-06-30	2024-04-01	Eiger Group Int Inc	Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions
WO2019178516A1 (en) *	2018-03-16	2019-09-19	SEN-JAM Pharmaceutical LLC	Methods and compositions to treat enteropathic arthritis
KR102422449B1 (ko) *	2019-10-18	2022-07-20	연세대학교 산학협력단	결핵 및 비결핵항산균 감염 질환의 예방, 개선 또는 치료용 조성물
KR20230039979A (ko) *	2021-09-15	2023-03-22	서울대학교산학협력단	아토피 피부염 예방 또는 치료용 겔 조성물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1101104A (en) *	1965-06-02	1968-01-31	Joseph Glasser	Compositions for the treatment of psoriasis
US4444780A (en) *	1982-08-30	1984-04-24	Ortho Pharmaceutical Corporation	Method for treating atopic dermatitis
AU8910891A (en) *	1990-11-20	1992-06-11	National Heart & Lung Institute, The	Treatment of lung diseases
DE69528773T2 (de) *	1994-10-05	2003-09-04	Cari Loder	Behandlung von multipler sklerose (ms) und anderen demyelinisationserkrankungen unter verwendung von lofepramin in kombination mit l-phenylalamin, tyrosin oder tryptophan und evtl. einer vitamin b12-verbindung
GB9619631D0 (en) *	1996-09-20	1996-11-06	British Biotech Pharm	Combination therapy
FI104363B (fi) *	1997-05-19	2000-01-14	Timo Kalevi Korpela	Immunosuppressanttien ja interferonien farmakologisten keskinäisten vaikutusten parantaminen lisäaineilla
US6372234B1 (en) *	1997-05-27	2002-04-16	Sembiosys Genetics Inc.	Products for topical applications comprising oil bodies
SK180499A3 (en) *	1997-07-01	2001-08-06	Pfizer	Sertraline salts and sustained-release dosage forms of sertraline
IN188720B (pl) *	1997-11-06	2002-11-02	Panacea Biotec Ltd
US6140337A (en) *	1997-12-23	2000-10-31	Schering Corporation	Methods for the treatment of mental disorders
US6423721B1 (en) *	1998-09-10	2002-07-23	Schering Corporation	Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
WO2000035454A1 (en) *	1998-12-18	2000-06-22	Du Pont Pharmaceuticals Company	N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US20020006961A1 (en) *	1999-05-14	2002-01-17	Katz Stanley E.	Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response
US20020061281A1 (en) *	1999-07-06	2002-05-23	Osbakken Robert S.	Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
AU2001261248A1 (en) *	2000-05-08	2001-11-20	David Haines	Immunosuppressive compositions comprising an immunophilin-binding compound and a gingkolide compound
AU2001296542B2 (en) *	2000-10-02	2007-10-25	Emory University	Triptolide analogs for the treatment of autoimmune and inflammatory disorders
US6599914B2 (en) *	2001-04-24	2003-07-29	Schering Corporation	Inhibition of cytokine generation
US7034059B2 (en) *	2001-07-02	2006-04-25	Sepracor Inc.	Methods of using norfluoxetine
WO2004030618A2 (en) *	2002-09-24	2004-04-15	Combinatorx, Incorporated	Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20050192261A1 (en) *	2003-09-15	2005-09-01	Jost-Price Edward R.	Methods and reagents for the treatment of immunoinflammatory disorders
EP1675550A4 (en) *	2003-09-24	2007-10-10	Combinatorx Inc	THERAPEUTIC DOSAGE DIAGRAMS FOR ADMINISTRATION OF MEDICINAL COMBINATIONS

2004
- 2004-02-12 JP JP2006503514A patent/JP2006517969A/ja not_active Withdrawn
- 2004-02-12 CA CA002514061A patent/CA2514061A1/en not_active Abandoned
- 2004-02-12 HR HR20050804A patent/HRP20050804A2/hr not_active Application Discontinuation
- 2004-02-12 TW TW093103296A patent/TW200509958A/zh unknown
- 2004-02-12 TW TW097127777A patent/TW200902047A/zh unknown
- 2004-02-12 WO PCT/US2004/004077 patent/WO2004073614A2/en not_active Ceased
- 2004-02-12 AU AU2004212919A patent/AU2004212919A1/en not_active Abandoned
- 2004-02-12 EP EP04710606A patent/EP1599212A4/en not_active Withdrawn
- 2004-02-12 US US10/777,518 patent/US20040224876A1/en not_active Abandoned
- 2004-02-12 KR KR1020057015072A patent/KR20050110634A/ko not_active Withdrawn
- 2004-02-12 PL PL378108A patent/PL378108A1/pl not_active Application Discontinuation
- 2004-02-12 MX MXPA05008649A patent/MXPA05008649A/es unknown
- 2004-02-16 AR ARP040100470A patent/AR043188A1/es unknown
2005
- 2005-07-29 NO NO20053678A patent/NO20053678L/no not_active Application Discontinuation
- 2005-09-13 IS IS8023A patent/IS8023A/is unknown

Also Published As

Publication number	Publication date
WO2004073614A3 (en)	2004-11-11
TW200509958A (en)	2005-03-16
MXPA05008649A (es)	2005-11-23
CA2514061A1 (en)	2004-09-02
KR20050110634A (ko)	2005-11-23
HRP20050804A2 (en)	2006-02-28
EP1599212A4 (en)	2006-02-08
AU2004212919A1 (en)	2004-09-02
US20040224876A1 (en)	2004-11-11
WO2004073614A2 (en)	2004-09-02
JP2006517969A (ja)	2006-08-03
EP1599212A2 (en)	2005-11-30
IS8023A (is)	2005-09-13
TW200902047A (en)	2009-01-16
PL378108A1 (pl)	2006-03-06
AR043188A1 (es)	2005-07-20
NO20053678D0 (no)	2005-07-29

Legal Events

Date	Code	Title	Description
2009-10-05	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20053678L (no)	2005-09-12	Kombinasjonsterapi for behandling av immuninflammatoriske forstyrrelser
NO20061239L (no)	2006-06-08	Fremgangsmater og reagenser for behandling av immunoinflammatoriske forstyrrelser
NO20062003L (no)	2006-07-07	Fremgangsmate og forbindelser for behandling av immunoinflammatoriske forstyrrelser
NO20074999L (no)	2007-12-03	Metode og preparat for behandling av perifere vaskulaere sykdommer
NO20052348L (no)	2005-08-02	Behandling av hemoragisk sjokk
DE60331236D1 (de)	2010-03-25	Orale zusammensetzungen zur behandlung von diabetes
NO20034549D0 (no)	2003-10-09	Behandling av type 2 diabetes med inhibitorer av dipeptidyl peptidase IV
NO20080113L (no)	2008-02-27	Kombinasjonsterapi for behandling av immunoinflammatorisk forstyrrelse
NO20065847L (no)	2006-12-18	Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
EP2331095A4 (en)	2012-03-21	CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
DK1525219T3 (da)	2009-09-07	GLP-1 og fremgangsm der til behandling af diabetes
ATE450269T1 (de)	2009-12-15	Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
NO20060328L (no)	2006-02-17	Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser
CY1110369T1 (el)	2015-04-29	Νεος συνεργιστικος συνδυασμος ο οποιος περιεχει ροφλουμιλαστη και φορμοτερολη
DK1781277T3 (da)	2012-05-07	Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
NO20051669L (no)	2005-06-10	Fremgangsmater og reagenser for behandling av sykdommer og forstyrrelser assosiert med okte nivaer av proinflammatoriske cytokiner
BR0310061A (pt)	2005-03-01	Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
NO20073104L (no)	2007-07-02	Anvendelse av en 5-HT6 agonist for behandling og forebygging av neurodegenerative forstyrrelser
DK1656131T3 (da)	2011-06-14	Anvendelse af betain til behandling claudicatio intermittens
TW200740441A (en)	2007-11-01	Methods and reagents for the treatment of inflammatory disorders
NO20073610L (no)	2007-09-12	Nye substituerte tiofenpyrimidinonderivater som inhibitorer for 17 β-hydroksysteroiddehydrogenase
WO2007047205A3 (en)	2007-10-04	Enzyme inhibitors of pai-1
NO20053023L (no)	2005-06-20	Synergistisk kombinasjon omfattende roflumilas og (R,R)-formoterol
ATE407925T1 (de)	2008-09-15	1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
ATE502637T1 (de)	2011-04-15	Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum